Identity
MariTide is a peptide–antibody conjugate combining GLP-1 agonism with GIP-receptor antagonism.
Selected study only; not a complete clinical review.
Peptide library
MariTide (Maridebart cafraglutide)
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The phase II study separates populations with and without diabetes. Treatment-policy estimates include discontinuation effects; a long-acting description does not establish that every patient can safely use a monthly schedule.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
592 adults with obesity, with or without diabetes; phase 2.
What the sources found
In participants without diabetes, 52-week treatment-policy weight changes ranged from −12.3% to −16.2% versus −2.5% with placebo.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
MariTide is a peptide–antibody conjugate combining GLP-1 agonism with GIP-receptor antagonism.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Reported adverse effects
- Gastrointestinal events were common and less frequent with dose escalation and a lower starting dose.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
In participants without diabetes, 52-week treatment-policy weight changes ranged from −12.3% to −16.2% versus −2.5% with placebo.
Selected study only; not a complete clinical review.
Adverseeffects
Gastrointestinal events were common and less frequent with dose escalation and a lower starting dose.
Selected study only; not a complete clinical review.
References
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. 2025.
PMID: 40549887
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.